Nivolumab for Esophageal Cancer
(CheckMate 577 Trial)

Recruiting in Palo Alto (17 mi)

+403 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Bristol-Myers Squibb

Pivotal Trial (Near Approval)

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This trial is testing if Nivolumab, a drug that helps the immune system fight cancer, can help cancer patients stay free of the disease longer. Nivolumab has been shown to improve survival in various cancers, including melanoma and esophageal cancer.

Eligibility Criteria

This trial is for people who've had surgery for Stage II/III esophageal or gastroesophageal junction cancer and still have some signs of the disease. They must have finished chemo radiotherapy before surgery. It's not open to those with other conditions that could interfere.

Inclusion Criteria

I had surgery for cancer with clear margins but still have some disease left.

I finished chemo and radiation before surgery.

My cancer is in the esophagus or where the stomach meets the esophagus, and it's at an advanced stage but not the most severe.

Participant Groups

The study is testing if Nivolumab, an immune therapy drug, can keep cancer from coming back better than a placebo (a treatment with no active drug). Participants will be randomly assigned to receive either Nivolumab or the placebo.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: NivolumabExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:

🇺🇸 Approved in United States as Opdivo for: